thinkpool

특허취득 
 
 
  증권거래법 제186조의 규정에 의하여 당사의 주요경영사항에 대해 다음과 같이 신고ㆍ공시 
  합니다. 
 
 
                                 2006  년    9 월     19일 
 
                              금융감독위원회(금융감독원) 귀중 
 
 
  회   사   명 :                주식회사 씨티씨바이오 
       (영문명)                 CTCBIO INC. 
       (홈페이지)               http://www.ctcbio.com 
 
 
  본 점 소 재 지 :              서울시 송파구 오금동 93번지 
       (전   화)                02-3400-9873 
 
 
  대 표 이 사 :                  조호연 . 김성린 
 
 
  담 당 임 원 :                 (직  책) 상무이사 
                                (성  명) 이정효               (전  화) 02-3400-9873 
 
 
 
  작   성   자 :                (직  책) 차장 
                                (성  명) 정휘경               (전  화) 02-3400-9873 
 
 
 
  제 출 이 유 :                               유가증권의발행및공시등에관한규정 제69조제1항 
                                              제5호마목에 의한 
                                              특허취득 
+------------------------------------------------------------------------------------------+ 
| ※ 본 건 금융감독위원회(금융감독원)에 제출하는 주요경영사항 신고는 증권거래법 제186조,   | 
| 동법 시행령 제83조 및 유가증권의발행및공시등에관한규정 제69조에 의한 『법정공시사항』    | 
| 으로 그 내용에 허위, 중요사실의 누락이 있을 경우 증권거래법 제206조의11, 제207조의3에    | 
| 의거 과징금 부과, 형사처벌 등 제재를 받을 수 있습니다.                                   | 
+------------------------------------------------------------------------------------------+ 
+-------------------------------------------+----------------------------------------------+ 
| 1. 특허명칭                               | 시부트라민 유리염기 함유 조성물 및 이의 제조 | 
|                                           | 방법                                         | 
+-------------------------------------------+----------------------------------------------+ 
| 2. 특허 주요내용                          |                                              | 
|                                           | 1. 본 특허는 비만치료제로서의 시부트라민 염  | 
|                                           | 산염 일수화물 또는 시부트라민 메탄술폰산염   | 
|                                           | 반수화물이 가진 염산염 또는 메탄술폰산의 바  | 
|                                           | 람직하지 않은 문제점을 극복하여 동등한 약리  | 
|                                           | 효과를 나타내는 비만치료제의 조성물 및 그의  | 
|                                           | 제조방법에 관하여 취득한 대한민국 특허임     | 
|                                           |                                              | 
|                                           | 2. 본 발명은 시부트라민 유리염기를 함유하는  | 
|                                           | 조성물에 관한 것으로서, 시부트라민 유리염기, | 
|                                           |  산 및 수용성 고분자가 균일하게 분산되어 함  | 
|                                           | 유된 고체분산체 및 그의 제조방법을 제공함.   | 
|                                           |                                              | 
|                                           | 3. 본 발명에 의한 조성물은 통상적인 시부트라 | 
|                                           | 민 유리염기 및 시부트라민 염산염 일수화물에  | 
|                                           | 비하여 뛰어난 용출률을 나타낼 수 있고, 대량  | 
|                                           | 생산이 용이하며 안정성이 양호함              | 
|                                           |                                              | 
+-------------------------------------------+----------------------------------------------+ 
| 3. 특허권자                               | (주)씨티씨바이오                             | 
+-------------------------------------------+----------------------------------------------+ 
| 4. 특허취득일자                           |               2006년 09월 18일               | 
+-------------------------------------------+----------------------------------------------+ 
| 5. 특허 활용계획                          | 1. 비만치료제의 제조 및 판매                 | 
|                                           | 2. 해외 또는 국내 제약관련기업에 대한 기술   | 
|                                           | 판매                                         | 
+-------------------------------------------+----------------------------------------------+ 
| 6. 확인일자                               |               2006년 09월 18일               | 
+------------------------------------------------------------------------------------------+ 
7. 기타 투자판단에 참고할 사항 
-특이사항 없음